albuterol has been researched along with No-Reflow Phenomenon in 1 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
No-Reflow Phenomenon: Markedly reduced or absent REPERFUSION in an infarct zone following the removal of an obstruction or constriction of an artery.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kopetz, V | 1 |
| Kennedy, J | 1 |
| Heresztyn, T | 1 |
| Stafford, I | 1 |
| Willoughby, SR | 1 |
| Beltrame, JF | 1 |
1 trial available for albuterol and No-Reflow Phenomenon
| Article | Year |
|---|---|
Endothelial function, oxidative stress and inflammatory studies in chronic coronary slow flow phenomenon patients.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Albuterol; Biomarkers; Coronary Disease; Endothelium, Vas | 2012 |